12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Benlysta belimumab regulatory update

Health benefits manager Aetna said Benlysta belimumab is medically necessary for its members with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy and meet...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >